{"id":22,"date":"2019-04-23T00:02:31","date_gmt":"2019-04-23T00:02:31","guid":{"rendered":"https:\/\/www.cutaquigus.com\/hcp\/evidence\/efficacy\/"},"modified":"2025-01-29T00:32:06","modified_gmt":"2025-01-29T00:32:06","slug":"evidence","status":"publish","type":"page","link":"https:\/\/cutaquigusa.com\/hcp\/evidence\/","title":{"rendered":"Evidence"},"content":{"rendered":"\n

In Phase 3 Pivotal and Extension Trials<\/h2>\n

Cutaquig Demonstrated Excellent Protection From Infection and Related Outcomes in Both Adult and Pediatric Patients 2 Years of Age and Older With PI1,2,3,4<\/sup><\/b><\/h3>\n

SUMMARY OF EFFICACY RESULTS:<\/b> All Patients (Adults, Children, Adolescents)*†<\/sup><\/h4>\n

\"\"<\/a><\/p>\n

\"\"<\/a><\/p>\n

\n
\n
\n

Efficacy Endpoints by Patient Age Were Similar<\/h3>\n\n\n\n\n\n\n\n\n\n\n
<\/th>\nPIVOTAL TRIAL*<\/th>\nEXTENSION TRIAL†<\/sup><\/th>\n<\/tr>\n
EFFICACY ENDPOINTS<\/th>\nAdults (n=37)<\/th>\nPediatrics (n=38)<\/th>\nAdults (n=17)<\/th>\nPediatrics (n=10)<\/th>\n<\/tr>\n<\/thead>\n
SBIs—Annual rate<\/th>\n0<\/td>\n0<\/td>\n0.03<\/td>\n0<\/td>\n<\/tr>\n
Other Infections
\nAnnual rate (per person-year)<\/th>\n		3.4<\/td>\n3.1<\/td>\n2.3<\/td>\n2.0<\/td>\n<\/tr>\n
Absence from work, school, or daycare
\nAnnual rate (days per person-year)<\/th>\n		2.0<\/td>\n5.2<\/td>\n1.7<\/td>\n3.6<\/td>\n<\/tr>\n
Hospitalizations Due to Infection
\nNumber of patients<\/th>\n		0<\/td>\n4<\/td>\n3<\/td>\n0<\/td>\n<\/tr>\n
Annual rate (days per person-year)<\/th>\n0<\/td>\n0.8<\/td>\n0.3<\/td>\n0<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

*<\/sup> In the pivotal trial, as no SBIs were reported, no specific statistical analyses for SBIs were performed. Secondary endpoints assessed include the number of episodes of any other infections, along with type and severity of infection and time to resolution, days out of work\/school\/kindergarten\/daycare due to infections, and the number of days and annual rate of hospitalization due to infections.<\/p>\n

†<\/sup> In the extension trial, secondary outcome measures include occurrence of SBIs, the number of episodes of any other infections, along with type and severity of infection and time to resolution, days out of work\/school\/kindergarten\/daycare due to infections, and the number of days and annual rate of hospitalization due to infections.<\/p>\n<\/div>\n<\/div>\n<\/section>\n

\n
\n
\n

Clinical study (SCGAM-01) design1,2<\/sup><\/h2>\n<\/div>\n<\/div>\n<\/section>\n
\n
\n
\"PK<\/a><\/div>\n
<\/div>\n
<\/div>\n<\/div>\n<\/section>\n
\n
\n
\n
\n
\n
<\/div>\n

Download the phase 3 clinical trial.<\/h3>\n

Kobayashi RH et al. Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (cutaquig®<\/sup>) in the Treatment of Patients with Primary Immunodeficiencies<\/p>\n

Download Now <\/i><\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n

\n
\n
\n
\n
\n
<\/div>\n

Download the pediatric clinical trial.<\/h3>\n

Kobayashi RH et al. Treatment of children with primary immunodeficiencies with a subcutaneous immunoglobulin 16.5% (cutaquig®<\/sup> [octanorm])<\/p>\n

Download Now <\/i><\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n

\n
\n
\n
\n
\n
<\/div>\n

Download the extension trial.<\/h3>\n

Kobayashi RH et al. Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®<\/sup>) in the treatment of patients with primary immunodeficiencies<\/p>\n

Download Now <\/i><\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n

\n
\n
\n
\n
\n
<\/div>\n

Review cutaquig safety and tolerability.<\/h3>\n

Learn More <\/i><\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n

\n
\n
\n
References:<\/h5>\n
    \n
  1. Kobayashi RH, Gupta S, Melamed I, et al. Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (octanorm [cutaquig®<\/sup>]) in the Treatment of Patients with Primary Immunodeficiencies. Front Immunol. February 2019 | Volume 10 | Article 40.<\/li>\n
  2. Cutaquig Full Prescribing Information. Paramus, NJ: Octapharma; rev October 2021.<\/li>\n
  3. Kobayashi RH, et al. Immunotherapy. 2021;13(10):813–824.<\/li>\n
  4. Kobayashi RH, et al., Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®<\/sup>) in the treatment of patients with primary immunodeficiencies, Clinical and Experimental Immunology. 2022; 210: 91–103.<\/li>\n<\/ol>\n<\/div>\n<\/div>\n<\/section>\n\n","protected":false},"excerpt":{"rendered":"

    In Phase 3 Pivotal and Extension Trials Cutaquig Demonstrated Excellent Protection From Infection and Related Outcomes in Both Adult and…<\/p>\n","protected":false},"author":29,"featured_media":0,"parent":0,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-22","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nEfficacy for cutaquig\u00ae SCIg Therapy Use for PI | cutaquig\u00ae<\/title>\n<meta name=\"description\" content=\"Review the efficacy data for cutaquig\u00ae (Immune Globulin Subcutaneous [Human]-hipp, 16.5% solution). Please see Important Safety Info including boxed warning.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cutaquigusa.com\/hcp\/evidence\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Efficacy for cutaquig\u00ae SCIg Therapy Use for PI | cutaquig\u00ae\" \/>\n<meta property=\"og:description\" content=\"Review the efficacy data for cutaquig\u00ae (Immune Globulin Subcutaneous [Human]-hipp, 16.5% solution). Please see Important Safety Info including boxed warning.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cutaquigusa.com\/hcp\/evidence\/\" \/>\n<meta property=\"og:site_name\" content=\"cutaquig\u00ae Healthcare Professionals\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/igcares\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-29T00:32:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cutaquigusa.com\/hcp\/wp-content\/uploads\/sites\/2\/2025\/01\/cutaquig_logo_1200x675.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/cutaquigusa.com\/hcp\/wp-content\/uploads\/sites\/2\/2025\/01\/cutaquig_logo_1200x675.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":[\"WebPage\",\"MedicalWebPage\"],\"@id\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/evidence\\\/\",\"url\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/evidence\\\/\",\"name\":\"Efficacy for cutaquig\u00ae SCIg Therapy Use for PI | cutaquig\u00ae\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/evidence\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/evidence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2022\\\/04\\\/Summary-of-Efficacy-Results_v2.png\",\"datePublished\":\"2019-04-23T00:02:31+00:00\",\"dateModified\":\"2025-01-29T00:32:06+00:00\",\"description\":\"Review the efficacy data for cutaquig\u00ae (Immune Globulin Subcutaneous [Human]-hipp, 16.5% solution). Please see Important Safety Info including boxed warning.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/evidence\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/evidence\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/evidence\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2022\\\/04\\\/Summary-of-Efficacy-Results_v2.png\",\"contentUrl\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2022\\\/04\\\/Summary-of-Efficacy-Results_v2.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/evidence\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evidence\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/#website\",\"url\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/\",\"name\":\"cutaquig\u00ae Healthcare Professionals\",\"description\":\"Cutaquig\u00ae [Immune Globulin Subcutaneous (Human) - hipp]\",\"publisher\":{\"@id\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/#organization\",\"name\":\"Cutaquig\u00ae\",\"url\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2025\\\/01\\\/cutaquig_logo_696x696.jpg\",\"contentUrl\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2025\\\/01\\\/cutaquig_logo_696x696.jpg\",\"width\":696,\"height\":696,\"caption\":\"Cutaquig\u00ae\"},\"image\":{\"@id\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/igcares\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Efficacy for cutaquig\u00ae SCIg Therapy Use for PI | cutaquig\u00ae","description":"Review the efficacy data for cutaquig\u00ae (Immune Globulin Subcutaneous [Human]-hipp, 16.5% solution). Please see Important Safety Info including boxed warning.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cutaquigusa.com\/hcp\/evidence\/","og_locale":"en_US","og_type":"article","og_title":"Efficacy for cutaquig\u00ae SCIg Therapy Use for PI | cutaquig\u00ae","og_description":"Review the efficacy data for cutaquig\u00ae (Immune Globulin Subcutaneous [Human]-hipp, 16.5% solution). Please see Important Safety Info including boxed warning.","og_url":"https:\/\/cutaquigusa.com\/hcp\/evidence\/","og_site_name":"cutaquig\u00ae Healthcare Professionals","article_publisher":"https:\/\/www.facebook.com\/igcares","article_modified_time":"2025-01-29T00:32:06+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/cutaquigusa.com\/hcp\/wp-content\/uploads\/sites\/2\/2025\/01\/cutaquig_logo_1200x675.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_image":"https:\/\/cutaquigusa.com\/hcp\/wp-content\/uploads\/sites\/2\/2025\/01\/cutaquig_logo_1200x675.jpg","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","MedicalWebPage"],"@id":"https:\/\/cutaquigusa.com\/hcp\/evidence\/","url":"https:\/\/cutaquigusa.com\/hcp\/evidence\/","name":"Efficacy for cutaquig\u00ae SCIg Therapy Use for PI | cutaquig\u00ae","isPartOf":{"@id":"https:\/\/cutaquigusa.com\/hcp\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cutaquigusa.com\/hcp\/evidence\/#primaryimage"},"image":{"@id":"https:\/\/cutaquigusa.com\/hcp\/evidence\/#primaryimage"},"thumbnailUrl":"https:\/\/cutaquigusa.com\/hcp\/wp-content\/uploads\/sites\/2\/2022\/04\/Summary-of-Efficacy-Results_v2.png","datePublished":"2019-04-23T00:02:31+00:00","dateModified":"2025-01-29T00:32:06+00:00","description":"Review the efficacy data for cutaquig\u00ae (Immune Globulin Subcutaneous [Human]-hipp, 16.5% solution). Please see Important Safety Info including boxed warning.","breadcrumb":{"@id":"https:\/\/cutaquigusa.com\/hcp\/evidence\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cutaquigusa.com\/hcp\/evidence\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cutaquigusa.com\/hcp\/evidence\/#primaryimage","url":"https:\/\/cutaquigusa.com\/hcp\/wp-content\/uploads\/sites\/2\/2022\/04\/Summary-of-Efficacy-Results_v2.png","contentUrl":"https:\/\/cutaquigusa.com\/hcp\/wp-content\/uploads\/sites\/2\/2022\/04\/Summary-of-Efficacy-Results_v2.png"},{"@type":"BreadcrumbList","@id":"https:\/\/cutaquigusa.com\/hcp\/evidence\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cutaquigusa.com\/hcp\/"},{"@type":"ListItem","position":2,"name":"Evidence"}]},{"@type":"WebSite","@id":"https:\/\/cutaquigusa.com\/hcp\/#website","url":"https:\/\/cutaquigusa.com\/hcp\/","name":"cutaquig\u00ae Healthcare Professionals","description":"Cutaquig\u00ae [Immune Globulin Subcutaneous (Human) - hipp]","publisher":{"@id":"https:\/\/cutaquigusa.com\/hcp\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cutaquigusa.com\/hcp\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cutaquigusa.com\/hcp\/#organization","name":"Cutaquig\u00ae","url":"https:\/\/cutaquigusa.com\/hcp\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cutaquigusa.com\/hcp\/#\/schema\/logo\/image\/","url":"https:\/\/cutaquigusa.com\/hcp\/wp-content\/uploads\/sites\/2\/2025\/01\/cutaquig_logo_696x696.jpg","contentUrl":"https:\/\/cutaquigusa.com\/hcp\/wp-content\/uploads\/sites\/2\/2025\/01\/cutaquig_logo_696x696.jpg","width":696,"height":696,"caption":"Cutaquig\u00ae"},"image":{"@id":"https:\/\/cutaquigusa.com\/hcp\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/igcares"]}]}},"_links":{"self":[{"href":"https:\/\/cutaquigusa.com\/hcp\/wp-json\/wp\/v2\/pages\/22","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cutaquigusa.com\/hcp\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cutaquigusa.com\/hcp\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cutaquigusa.com\/hcp\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/cutaquigusa.com\/hcp\/wp-json\/wp\/v2\/comments?post=22"}],"version-history":[{"count":0,"href":"https:\/\/cutaquigusa.com\/hcp\/wp-json\/wp\/v2\/pages\/22\/revisions"}],"wp:attachment":[{"href":"https:\/\/cutaquigusa.com\/hcp\/wp-json\/wp\/v2\/media?parent=22"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}